Abstract. Two major species of human apolipoprotein (apo) B have been identified, apo B-48 and apo B-100, which are the predominant forms in chylomicrons and very low density lipoproteins (VLDL), respectively. Due to defective hepatic clearance, apo B-48 containing lipoproteins accumulate in the plasma of subjects with type III hyperlipoproteinemia. In the present study, we have used immunoaffinity chromatography to separate type III VLDL into a nonretained (apo B-48 VLDL) and a retained (apo B-100 VLDL) fraction. To achieve complete separation, as determined by electrophoresis and radioimmunoassay, it was necessary to employ two different insolubilized anti-apo B-100 monoclonal antibodies because of immunochemical heterogeneity within the apo B-100 VLDL fraction. The ability to separate apo B-I00 VLDL from apo B-48 VLDL shows that the two apo B species are found on different particles. The apo B-48 VLDL had an electrophoretic mobility similar to chylomicrons, whereas the apo B-100 VLDL migrated similarily to total type III VLDL. Both fractions showed a concentration ofparticles with diameters -100 nm, with apo B-48 VLDL being somewhat more heterogeneous in particle size. The two fractions were qualitatively similar in apolipoprotein composition but apo B-48 VLDL was enriched in apo E, relative to apo BDr. Milne is a scholar of the Fondation de la Recherche en Sante du Quebec.
achieve complete separation, as determined by electrophoresis and radioimmunoassay, it was necessary to employ two different insolubilized anti-apo B-100 monoclonal antibodies because of immunochemical heterogeneity within the apo B-100 VLDL fraction. The ability to separate apo B-I00 VLDL from apo B-48 VLDL shows that the two apo B species are found on different particles. The apo B-48 VLDL had an electrophoretic mobility similar to chylomicrons, whereas the apo B-100 VLDL migrated similarily to total type III VLDL. Both fractions showed a concentration ofparticles with diameters -100 nm, with apo B-48 VLDL being somewhat more heterogeneous in particle size. The two fractions were qualitatively similar in apolipoprotein composition but apo B-48 VLDL was enriched in apo E, relative to apo BDr. Milne is a scholar of the Fondation de la Recherche en Sante du Quebec.
Introduction
Substantial attention has been given to lipoprotein disorders of subjects with type III hyperlipoproteinemia, despite the comparative rarity of this phenotype among subjects with familial hyperlipidemias. The clinical characteristics of familial type III hyperlipoproteinemia have been reviewed (1) and include a high incidence of premature peripheral and coronary artery disease, lipid deposition in tissues, especially in the form of tuberous xanthomas and planer xanthomas in creases, rapid normalization of the hyperlipidemia following simple treatment, and several typical lipoprotein abnormalities. The lipoprotein abnormalities are themselves threefold: (a) a dysbetalipoproteinemia that presents itself as a noticeable quantity of very low density lipoprotein (VLDL) with ,B-electrophoretic mobility, cholesterol-enriched VLDL, abnormalities in the E apoprotein (2) (3) (4) (5) , and an elevated plasma apolipoprotein (apo) E concentration (6) ; (b) a hyperlipidemia that may be inherited (familial combined hyperlipidemia) or acquired (hypothyroidism) independently ofthe mutant apo E gene that may be superimposed on the dysbetalipoproteinemia (7, 8) ; and (c) an overproduction of apo B is concurrent with the hyperlipidemia peculiar to hyperlipidemic dysbetalipoproteinemia, with a greater-than-proportional overproduction of apo B in an otherwise minor ((i) pathway in the VLDL, and direct input into the intermediate density lipoprotein (IDL) (9, 10) . Other factors, including age and obesity, may also play a role in the expression of the type III phenotype.
In recent years it has become evident that human apo B is chemically and physically heterogeneous. The principal species of apo B in normal human VLDL and low density lipoprotein (LDL) has an apparent molecular weight in sodium dodecyl sulphate (SDS) of 549,000 and has been termed apo B-100 in a centile system of nomenclature based on molecular weight. The predominant apo B form in human chylomicrons, apo B-48, has a molecular weight of 264,000 and is not found in normal LDL (1 1). The amino acid composition of apo B-48 is different from that of apo B-100 (I 1) although immunological cross-reactivity exists between the two species (12, 13) . There is evidence to suggest that the synthesis of apo B-100 and apo B-48 is under separate genetic control (14) . Two recent reports (15, 16) have described the presence of apo B-48 in the VLDL of subjects with familial type III hyperlipoproteinemia.
We have described the production and characterization of a series of monoclonal antibodies against human apo B-100 (12, 17, 18) . Of seven anti-apo B-100 antibodies, five did not react with apo B-48. Here we describe the use of some of these monoclonal antibodies for the separation of VLDL from type III hyperlipoproteinemic patients into two fractions that contain either apo B-48 or apo B-100 as their sole apo B proteins. We show that the apo B-48 and apo B-100 are on different lipoprotein particles and that the two VLDL subfractions differ in their physicochemical properties. This study furthermore demonstrates that there is immunochemical heterogeneity in apo B expression within the apo B-100 containing VLDL.
Methods
Experimental subjects. The plasma used for these studies was derived from eight subjects (seven males) with the E2/2 apo E phenotype as determined by the technique of Bouthillier et al. (19) . The diagnosis of type III dysbetalipoproteinemia had been established at a prior visit at the lipid clinic on the basis of elevated plasma cholesterol (>250 mg/ dl) and/or elevated plasma triglycerides (>200 mg/dl) with one or more of the following characteristics of type III: typical skin xanthomas, a broad betaband, the presence of fl-VLDL, a VLDL-cholesterol/triglyceride ratio of 0.30 or more, or equally high levels of plasma cholesterol and triglycerides. A large amount of plasma from one patient whose cholesterol was 345 mg/dl and triglycerides were 404 mg/dl at the time of sampling was used for all the studies used to validate the separation technique. Plasma samples from the other seven patients were pooled for all the analytical studies.
Preparation oflipoproteins. Blood from normal subjects or patients with type III hyperlipoproteinemia was collected after a 14-h fast into EDTA and the red blood cells were removed by centrifugation. Lipoprotein fractions were prepared by floatation in a Beckman L5-65 ultracentrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) with a 50.2 Ti rotor at 50C, 45,000 rpm for 20 h. LDL were isolated from normal subjects by successive ultracentrifugation (20) at 4°C between densities of 1.030 and 1.050 g/ml. The VLDL and IDL from type III hyperlipoproteinemic subjects were isolated at densities of 1.006 g/ml and of 1.006-1.019 g/ml, respectively. The lipoprotein subfractions were dialyzed against phosphate-buffered saline (PBS) containing I mM EDTA and 0.02% N3Na and stored at 40C.
Monoclonal antibodies and antisera. Monoclonal antibodies against human apo B have been reported (12, 17) . Affinity-purified rabbit antimouse IgG was purchased from Kirkegaard and Perry Laboratories, Inc. (Gaithersburg, MD). The preparation of antisera used in the electroimmunoassays are described in the relevant reference for each apolipoprotein assay.
Immunoadsorbants and affinity chromatography. The IgG was precipitated from the ascitic fluid of mice bearing the hybridomas 4G3 or SEl 1 with 40% saturated ammonium sulphate. The precipitated protein was redissolved in and dialyzed against 0.1 M sodium bicarbonate, pH 8 30 Mg protein/ml in 5 mM glycine, pH 9.2 (buffer B), was added to Removawells (Dynatech Laboratories, Inc., Alexandria, VA), and left overnight at room temperature. The following day the wells were washed in 0.15 M NaCI containing 0.025% Tween 20 (buffer C) and then exposed for 30 min at room temperature to 300 Ml of buffer A to saturate the plastic. 200-Ml aliquots of the sample-antibody mixtures were added to the wells and left for 24 h at room temperature. The wells were washed in buffer C and 250 Ml of '25I-anti-mouse IgG diluted in buffer A was added to the wells. After an overnight incubation the wells were washed as described above and the bound radioactivity was determined. Results are expressed as B/Bo, where B = cpm bound -cpm nonspecifically bound and Bo = cpm bound in the absence of sample -cpm nonspecifically bound. Nonspecific binding was determined in wells in which the sample was replaced by LDL diluted to 100 Mg protein/ml. The intraassay coefficient of variation for the measurement of VLDL was 10%.
Quantitative determination of apolipoprotein. The quantitative determination of VLDL-associated apoproteins was carried out by previously described procedures for apoproteins A-I and A-Il (22), B (23), C-I (24), C-II (24), C-III (25) , and E (6).
Lipid analysis. From pooled VLDL prepared from type III patients we took samples of VLDL, apo B-48 VLDL, and apo B-100 VLDL fractions estimated to contain -200 Mug protein. After lyophilizing these samples, the procedures described by Kuksis et al. (26) were used for digestion with 0.3 mg phospholipase C (Sigma Chemical Co., St. Louis, Lipoprotein analysis. The apolipoprotein composition of the VLDL subfractions was assessed by SDS (27) and tris-urea (28) polyacrylamide gel electrophoresis. To identify apo B-100 and apo B-48 in type III VLDL and its subfractions, SDS polyacrylamide gel electrophoresis was carried out according to Kane et al. (11) . Paper electrophoresis in an albumin-containing buffer was performed according to Lees and Hatch (29) . For electron microscopy, samples were negatively stained with potassium phosphotungstate (30) and the diameters of particles were measured directly on the calibrated positive plates. Protein concentration was measured by the Lowry technique (31).
Results
Capacity ofanti-apo B-100 immunoadsorbants. Two monoclonal antibodies, 4G3 and 5E1 1 (12, 17) , were chosen on the basis of their lack of cross-reactivity against apo B-48. The IgG fractions, partially purified from the ascitic fluids of mice bearing the hybridomas 4G3 and 5E1 1, were covalently coupled to Sepharose. To The starting VLDL (.), the nonretained fraction (x), the retained fraction (eluted with acid) (o), as well as normal LDL (A) were tested in RIA using either antibodies SEl 1 or 4G3, which react only with apo B-l00, or 2D8, which reacts with both apo B-l00 and apo B-48.
nonretained fraction was divided in two and either passed on 4G3 Sepharose or repassed on 5E 1 Sepharose. The nonretained fractions were tested in RIA against 2D8, 4G3, and 5E 1 (Fig.  2) . Passage on 4G3 Sepharose of the fraction not retained by 5EI 1 removed almost all activity against 4G3, whereas repassage on 5EI 1 had little effect. Passage of type III VLDL directly on 4G3 Sepharose resulted in a nonretained fraction which showed 1.5% of the starting activity in RIA with 4G3 and 8% of the starting activity with 5E 1 (not shown).
SDS-polyacrylamide gel electrophoresis of the fractions bound and unbound (Fig. 3) These results suggested that, ifcare were taken to not overload the columns, apo B-48 VLDL could be prepared free of apo B-100 VLDL by sequential passage on 5E 1 and 4G3 immunoadsorbants. Thus, when 2 mg of type III VLDL was applied sequentially to the 5E 1 and 4G3 Sepharose, the nonretained fraction contained no apo B-I00 VLDL, and no apo B-48 VLDL was present in the retained fraction (Fig. 4) . The lack of apo B-100 in the nonretained fraction was confirmed in RIA against Physical characterization ofapo B-48 and apo B-J00 VLDL.
On paper electrophoresis the apo B-100 VLDL showed a migration similar to the starting VLDL (Fig. 5) . The apo B-48 VLDL, on the other hand, remained at the point ofapplication.
The particle size distribution is shown in Fig. 6 . In the case of the apo B-48 VLDL, particle diameters range from 20 to 260 nm with a concentration ofparticles -90 nm and a distribution skewed towards particles of larger diameter. The particles in the apo B-100 VLDL show a more restricted distribution, with 80% of particles having diameters between 55 and 140 nm. (Fig. 7 B) bands corresponding to apo E, apo CI (tentative identification), apo CII, apo CIII-0, apo CIII-1, and apo CIII-2 were seen in all fractions.
The apolipoprotein content of the three VLDL fractions was determined by electroimmunoassay and the results are shown in Table II . In percentage composition the apo B-100 VLDL was almost identical with the starting material. This is not surprising, as in all type III VLDL samples examined apo B-100 has represented the predominant apo B-species (e.g., Fig.  3, lane 1) . In contrast, apo B-48 VLDL was clearly different from the other two fractions. It should be noted that the apo B assay was performed with a polyclonal antiserum raised against LDL (i.e., apo B-100), and therefore the measured apo B content of apo B-48 VLDL may be incorrect. If this were the case, the calculated percentage composition for apo B-48 VLDL with respect to the other apoproteins would also be incorrect. From the absolute values, however, it is clear that in apo B-48 VLDL the ratio ofapo E to the individual apo C proteins was increased relative to apo B-100 VLDL. As the protein concentration of the apo B-48 VLDL sample was about one-half that of the apo B-100 VLDL sample, the increase in the apo E/apo C ratio of apo B-48 VLDL was due to an enrichment in apo E.
Discussion
Insolubilized monoclonal antibodies against human apo B-100 that show no cross-reactivity against apo B-48 can be used to separate apo B-48-containing particles from apo B-100 particles in the plasma VLDL fraction of patients with type III hyperlipoproteinemia. When care is taken not to overload the immunoadsorbant column, no apo B-100 is detected in the unbound apo B-48 VLDL by either SDS gel electrophoresis or by RIA. The fraction retained by the immunoadsorbants contains apo B-100 as the sole apo B species. While throughout this report we have referred to the nonretained and retained fractions as apo B-48 and apo B-100 VLDL, respectively, we do not exclude the possibility that these two fractions include subpopulations of particles containing only apolipoproteins other than apo B. The ability to separate apo B-100 VLDL from apo B-48 VLDL shows that, in the human, apo B-48 and apo B-100 are present on different particles. This would be expected if, as has been suggested, apo B-100 were entirely of hepatic origin and apo B-48 were synthesized uniquely by the intestine. This may not, on the other hand, be the case for the rat, in which hepatic synthesis of both apo B-100 and apo B48 has been demonstrated (34) (35) (36) .
This study also illustrates the existence of immunochemical heterogeneity in the apo B-100 VLDL. Subpopulations of apo B-100 VLDL exist in which the antigenic determinants SE1 1 and 4G3 are variably expressed. We have previously noted an increased reactivity of VLDL and chylomicrons upon partial delipidation (18 by SDS (Fig. 7 A) and tris-urea (Fig. 7 B) polyacrylamide gel electrophoresis. 50 ug of protein was applied to the gels. In Fig. 7 showed a similar electrophoretic mobility (characteristic ofchylomicrons) and a similar particle size distribution to the apo B-48 VLDL described here. Owing to differences in the starting material (fl-VLDL vs. total VLDL), the physical properties of the apo B-100-enriched fractions cannot be validly compared with those of the apo B-100 VLDL in the present report. The most striking difference in the apolipoprotein composition between the apo B-48 VLDL and the apo B-I OOVLDL fractions was the increased apo E/apo C ratio of the former as a result of a relative enrichment in apo E. In the rat it has been demonstrated that apo E and the C apoproteins can influence lipoprotein uptake by the liver (39, 40) . In addition to the apoproteins shown in Table II (43, 44) . The defect in catabolism of remnants in type III subjects is, at least in part, due to the presence of the apo E-2 isoform (2, 3) , which is poorly recognized by cell surface receptors (4, 5) and which shows retarded intravascular metabolism (45) . Since chylomicron remnants are cleared from plasma by the liver (46), which contains apo E receptors (47), we can imagine that the rate of input ofchylomicron remnants and their lipids into the liver is reduced in the type III subject. This might reduce the feedback inhibition of hepatic cholesterol synthesis, as has been observed in fibroblasts (48) , and cause overproduction and secretion ofcholesterol and apo B-100, possibly explaining both the overproduction of VLDL and IDL (9) and the abnormal cholesterol-enriched composition of the apo B-100 VLDL in these subjects.
In 
